Amgen announced today, April 3, 2005, that they have submitted a Biologic License Application (BLA) to the FDA for panitumumab for use in metastatic colorectal cancer where all current standard treatments have failed.
Previously they had announced the results of a Phase III clinical trial that compared panitumumab used as a single agent to best supportive care alone in colorectal cancer patients whose cancers had progressed on standard therapy. In that trial, there was a significant improvement in progression-free survival in patients who received panitumumab.
The trial will be discussed today at the annual meeting of the American Association for Cancer Research (AACR).
Leave a Reply
Your comments are welcome. However, specific medical advice will not be provided. Generic QUESTIONS can be directed to our Answer Line team at http://fightcolorectalcancer.org/awareness/answer-line or by calling us at 1-877-427-2111 9:00 AM – 5:00 PM Eastern time, Monday – Friday. We urge you to consult with a qualified physician for diagnosis and for answers to your personal questions. Fight Colorectal Cancer is not responsible for the medical accuracy of any comments left by persons other than Fight Colorectal Cancer staff members. Fight Colorectal Cancer staff members monitor comments and may respond publicly where appropriate.
Please note that we automatically publish the name that you enter next to your post. Also note that our pages are automatically indexed by Google and other search engines, and your name may therefore appear in search results on those sites. So if you wish to remain anonymous please use a different name or enter 'Anon' as the name.
We regret that we are unable to privately answer questions left as comments. So please do not include your phone number, email or mailing address in the body of your comment.